What is lumateperone and what does it treat? Lumateperone is a medication that works in the brain to treat schizophrenia. It is also known as a second generation antipsychotic (SGA) or atypical antipsychotic. Lumateperone rebalances dopamine, serotonin, and glutamate to improve thinking, mood, and behavior.

Caplyta is FDA-approved for the treatment of schizophrenia in adults and for depressive episodes in people with bipolar disorder. It works by affecting dopamine, serotonin, and glutamate in order to improve symptoms that affect mood, thoughts, and behaviors.

CAPLYTA is a once-daily pill proven to deliver significant symptom relief from bipolar I and bipolar II depression. CAPLYTA can be taken alone or with lithium or valproate.

The trial's patients had a mean baseline MADRS of about 31, and Caplyta on average led to an additional 5.7-point reduction versus placebo. The average reduction in patients with bipolar depression and major depressive disorder was 5.7 points and 5.9 points, respectively.

How long does it take Caplyta (lumateperone) to work? You can expect Caplyta (lumateperone) to start working in 1 to 2 weeks, but it may take several weeks until it takes full effect.

How long does it take Caplyta (lumateperone) to work? You can expect Caplyta (lumateperone) to start working in 1 to 2 weeks, but it may take several weeks until it takes full effect.

Caplyta has an average rating of 6.1 out of 10 from a total of 79 reviews for the treatment of Bipolar Disorder. 48% of reviewers reported a positive experience, while 33% reported a negative experience.

Caplyta belongs to the class of medicines known as atypical antipsychotics. Atypical means it is less likely than older antipsychotics to cause side effects, such as extrapyramidal symptoms (EPS).

Caplyta has an average rating of 5.7 out of 10 from a total of 134 ratings on Drugs.com. 45% of reviewers reported a positive effect, while 40% reported a negative effect. Seroquel has an average rating of 7.0 out of 10 from a total of 672 ratings on Drugs.com.

Response and effectiveness In Study 1, patients assigned Caplyta 42mg showed a statistically significant mean change from baseline PANSS of -13.2 compared to -7.4 with placebo. In study 2 the mean change from baseline PANSS was -14.5 with Caplyta compared to -10.3 with placebo.

CAPLYTA is available in 10.5 mg, 21 mg, and 42 mg capsules.